The fallacy of single-agent chemotherapy for cancer.
Publication
, Journal Article
Friedman, HS; Maxwell, J
Published in: J Clin Oncol
August 10, 2007
Duke Scholars
Published In
J Clin Oncol
DOI
EISSN
1527-7755
Publication Date
August 10, 2007
Volume
25
Issue
23
Start / End Page
3550
Location
United States
Related Subject Headings
- Temozolomide
- Sensitivity and Specificity
- Promoter Regions, Genetic
- Oncology & Carcinogenesis
- O(6)-Methylguanine-DNA Methyltransferase
- Humans
- Glioblastoma
- Dacarbazine
- Brain Neoplasms
- Biomarkers, Tumor
Citation
APA
Chicago
ICMJE
MLA
NLM
Friedman, H. S., & Maxwell, J. (2007). The fallacy of single-agent chemotherapy for cancer. J Clin Oncol, 25(23), 3550. https://doi.org/10.1200/JCO.2007.12.3596
Friedman, Henry S., and Jill Maxwell. “The fallacy of single-agent chemotherapy for cancer.” J Clin Oncol 25, no. 23 (August 10, 2007): 3550. https://doi.org/10.1200/JCO.2007.12.3596.
Friedman HS, Maxwell J. The fallacy of single-agent chemotherapy for cancer. J Clin Oncol. 2007 Aug 10;25(23):3550.
Friedman, Henry S., and Jill Maxwell. “The fallacy of single-agent chemotherapy for cancer.” J Clin Oncol, vol. 25, no. 23, Aug. 2007, p. 3550. Pubmed, doi:10.1200/JCO.2007.12.3596.
Friedman HS, Maxwell J. The fallacy of single-agent chemotherapy for cancer. J Clin Oncol. 2007 Aug 10;25(23):3550.
Published In
J Clin Oncol
DOI
EISSN
1527-7755
Publication Date
August 10, 2007
Volume
25
Issue
23
Start / End Page
3550
Location
United States
Related Subject Headings
- Temozolomide
- Sensitivity and Specificity
- Promoter Regions, Genetic
- Oncology & Carcinogenesis
- O(6)-Methylguanine-DNA Methyltransferase
- Humans
- Glioblastoma
- Dacarbazine
- Brain Neoplasms
- Biomarkers, Tumor